Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Gastric Cancer
Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer
FDA Approvals, News & Updates
,
Gastric Cancer
June 2021, Vol 12, No 3
On
May 5, 2021
, the FDA accelerated the approval of the PD-1 inhibitor pembrolizumab (Keytruda; Merck & Co), in combination with trastuzumab plus fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Read Article
Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer
FDA Approvals, News & Updates
,
Gastric Cancer
June 2021, Vol 12, No 3
On
April 16, 2021
, the FDA approved the PD-1 inhibitor nivolumab (Opdivo; Bristol Myers Squibb), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal adenocarcinoma. Nivolumab was the first immunotherapy approved by the FDA for first-line treatment of gastric cancer.
Read Article
Atezolizumab-Bevacizumab Combo Improves Survival and Quality of Life in Unresectable Liver Cancer
By
Wayne Kuznar
Gastric Cancer
June 2020, Vol 11, No 3
San Francisco, CA—The combination of atezolizumab (Tecentriq) immunotherapy plus bevacizumab (Avastin) improves survival as well as significantly delaying deterioration in quality of life compared with the current standard of the targeted therapy sorafenib (Nexavar) in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
Read Article
Promising 3-Drug Regimen for Advanced Gastric Cancer, Regardless of PD-L1 Expression
By
Wayne Kuznar
Gastric Cancer
June 2020, Vol 11, No 3
San Francisco, CA—Second-line treatment with a 3-drug regimen that included the PD-1 inhibitor nivolumab (Opdivo), the VEGF receptor antagonist ramucirumab (Cyramza), and chemotherapy with the taxane paclitaxel, showed durable and impressive response rates, regardless of PD-L1 expression, in patients with advanced gastric cancers. Shuichi Hironaka, MD, PhD, Chiba Cancer Center, Japan, reported the study results at the 2020 Gastrointestinal Cancers Symposium.
Read Article
Adding 2 Immunotherapies to Cabozantinib Extends Survival in Advanced Liver Cancer
Gastric Cancer
June 2020, Vol 11, No 3
San Francisco, CA—The addition of a second immunotherapy, ipilimumab (Yervoy), to the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) produced durable responses and longer progression-free survival (PFS) than cabozantinib plus nivolumab alone in patients with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer. The overall survival (OS) was not yet reached in the triplet arm.
Read Article
Ramucirumab Improves Survival as Second-Line Therapy in Patients with Advanced Gastric Cancer
By
Wayne Kuznar
Gastric Cancer
April 2014, Vol 5, No 3
San Francisco, CA—Phase 3 data from a global clinical trial have demonstrated an improvement in overall survival (OS) when the investigational angiogenesis inhibitor ramucirumab is added to chemotherapy as second-line therapy in patients with advanced gastric cancer.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma